Cellosaurus logo
expasy logo

Cellosaurus 1362-mel (CVCL_S560)

[Text version]
Cell line name 1362-mel
Synonyms 1362-MEL; 1362 mel; 1362mel; 1362
Accession CVCL_S560
Resource Identification Initiative To cite this cell line use: 1362-mel (RRID:CVCL_S560)
Comments From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
Derived from site: Metastatic; Not specified.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
HLA typing Source: PubMed=9670966
Class I
HLA-AA*01,25
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Sex unspecified
Age at sampling Age unspecified
Category Cancer cell line
Publications

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A., Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer 80:781-790(1999)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

Cross-references
Cell line databases/resources cancercelllines; CVCL_S560
CGH-DB; 9294-4
Encyclopedic resources Wikidata; Q54581657
Polymorphism and mutation databases Cosmic; 905208
Entry history
Entry creation03-Feb-2014
Last entry update05-Oct-2023
Version number15